← FDA DRUG APPROVALS

FDA ANDA · ANDA203853

ACETYLCYSTEINE

Sponsor: ALVOGEN

APPLICATION
ANDA203853
TYPE
ANDA
ORIGINAL APPROVAL
2012-06-21
LATEST ACTION
2012-06-21
ROUTE
ORAL, RESPIRATORY (INHALATION), INHALATION, ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ACETYLCYSTEINEPrescription
ACETYLCYSTEINE 20% · SOLUTION · INHALATION, ORAL

Approval history

2012-06-21UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →